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Summary
Human IL-10 (hIL-10) is a cytokine that modulates
diverse immune responses. The Epstein-Barr virus
(EBV) genome contains an IL-10 homolog (vIL-10) that
shares high sequence and structural similarity with
hIL-10. Although vIL-10 suppresses inflammatory re-
sponses like hIL-10, it cannot activate many other im-
munostimulatory functions performed by the cellular
cytokine. These functional differences have been
correlated with the 1000-fold lower affinity of vIL-10,
compared to hIL-10, for the IL-10R1 receptor chain.
To define the structural basis for these observations,
crystal structures of vIL-10 and a vIL-10 point mutant
were determined bound to the soluble IL-10R1 recep-
tor fragment (sIL-10R1) at 2.8 and 2.7 Å resolution,
respectively. The structures reveal that subtle
changes in the conformation and dynamics of the vIL-
10 AB and CD loops and an orientation change of vIL-
10 on sIL-10R1 are the main factors responsible for
vIL-10’s reduced affinity for sIL-10R1 and its distinct
biological profile.
Introduction
Human IL-10 (hIL-10) was first described as cytokine
synthesis inhibitory factor (CSIF) because it blocks the
production of proinflammatory cytokines, including
IL-1, TNF-α, IL-8, and GM-CSF (de Waal Malefyt et al.,
1991a; Fiorentino et al., 1989). Additional studies reveal
hIL-10 regulates opposing immunosuppressive and im-
munostimulatory functions (Moore et al., 2001). For ex-
ample, hIL-10 inhibits the expression of molecules in-
volved in antigen presentation and costimulation (de
Waal Malefyt et al., 1991b; Ding et al., 1993) but also
functions as a potent growth and differentiation factor
for thymocytes, mast cells, and B cells (Rousset et al.,
1992; Thompson-Snipes et al., 1991).
The functional hIL-10 receptor complex is composed
of at least two different cell surface receptor chains, IL-
10R1 and IL-10R2, which belong to the cytokine recep-
tor family type 2 (Kotenko et al., 1997; Liu et al., 1994).
The first step in the signal transduction pathway is the
interaction of hIL-10 with its high-affinity (dissociation
constant [Kd] w50–200 pM on cells) receptor, IL-10R1
(Liu et al., 1994; Tan et al., 1993). Subsequently, the in-
termediate IL-10/IL-10R1 complex binds to the low-
affinity receptor, IL-10R2. The active signaling complex,
hIL-10/IL-10R1/IL-10R2, induces the phosphorylation*Correspondence: walter@uab.eduof signal transducer and activator of transcription
(STAT3) by activating JAK family tyrosine kinases, Jak1
and Tyk2 (Kotenko et al., 1996, 1997; Usacheva et al.,
2002). Although IL-10R2 is critical for inducing hIL-10
biological activities, cell surface IL-10R2 does not dis-
play measurable binding affinity for hIL-10 alone or in
the presence of IL-10R1 (Ding et al., 2001; Kotenko et
al., 1997).
hIL-10 is essential for controlling and ultimately ter-
minating host inflammatory responses (Moore et al.,
2001). Consequently, numerous pathogens manipulate
endogenous IL-10 levels or harbor an IL-10 homolog in
their genome to promote their own survival and escape
from immune detection (Redpath et al., 2001). Pre-
viously, we performed structural studies on the IL-10
homolog from cytomegalovirus (cmvIL-10; Jones et al.,
2002). cmvIL-10 shares only 27% sequence identity
with hIL-10 (Kotenko et al., 2000; Lockridge et al.,
2000). In contrast to cmvIL-10, the Epstein-Barr virus
(EBV) contains an open reading frame (BCRF1) that
shares w83% sequence identity with hIL-10 (Figure 1;
Moore et al., 2001). EBV is a γ-1 herpes virus that in-
fects over 90% of the human population and is persis-
tent asymtomatically for life (Rickinson and Kieff, 2001).
More importantly, EBV causes infectious mononucleo-
sis and is associated with certain kinds of cancers, in-
cluding Burkitt’s lymphoma, Hodgkin’s disease, and na-
sopharyngeal carcinoma (Cohen, 2000).
BCRF1, which is often called vIL-10, is secreted from
EBV-infected cells, requires IL-10R1 and IL-10R2 to ini-
tiate signaling, and exhibits many of the biological
functions of hIL-10 (Liu et al., 1997; Moore et al., 2001).
vIL-10 retains the ability to suppress inflammatory cy-
tokine production and inhibit MHC II expression on mo-
nocytes and macrophages, and prevents T cell prolifer-
ation. However, in contrast to hIL-10, vIL-10 is unable
to costimulate thymocyte and mast cell proliferation
and does not induce B cell MHC class II expression (Go
et al., 1990; MacNeil et al., 1990; Vieira et al., 1991). The
different functional properties of vIL-10 are thought to
be the result of constant selective pressure on EBV to
gain an advantage over the host’s immune system.
These characteristics suggest vIL-10 may be more ef-
fective than hIL-10 as an immunosuppressant for trans-
plantation or the treatment of autoimmune and inflam-
matory disease (Ma et al., 1998; Minter et al., 2001a,
2001b; Qin et al., 1996).
Competitive binding studies, using 125I-labeled hIL-
10, reveal that vIL-10 exhibits w1000-fold lower affinity
for cell surface IL-10R1 than hIL-10 on human cells
alone or in the presence of IL-10R2 (Ding et al., 2001;
Liu et al., 1997). Based on these studies, Ding et al.
demonstrated that vIL-10 could not induce biological
responses in cells with low IL-10R1 levels while the
same cells remained responsive to hIL-10 (Ding et al.,
2001). This data further strengthens the argument that
the distinct biological activities of hIL-10 and vIL-10 are
mediated by differences in their affinities for IL-10R1.
Despite their large difference in affinity for IL-10R1, the
crystal structure of free vIL-10 was essentially identical
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552Figure 1. Sequence and Structure of vIL-10
(A) Structure-based sequence alignment based on vIL-10/sIL-10R1 and hIL-10/sIL-10R1 complexes. vIL-10 amino acids that differ from the
hIL-10 sequence are shown in bold. The approximate amount of surface area buried by residues in viral (vIL-10 and vIL-10A87I) and human
IL-10 is shown with black circles according to the following code; (5Å2 < one circle % 20Å2), (20Å2 < two circles %40Å2), (40Å2 < three cir-
cles % 60Å2), (60Å2 < four circles % 80Å2), (80Å2 < five circles % 100Å2), (>100Å2 = six circles). Residues that bury surface area only in vIL-
10 or only in vIL-10A87I are shown by black squares and open circles, respectively. If two markers are shown, the greatest position of each
marker reflects the amount of surface area buried in the respective complexes.
(B) Ribbon diagram of one vIL-10 domain. The side chains of vIL-10 residues that differ from hIL-10 are shown. vIL-10 residues that bury
surface area in the site Ia and Ib interfaces are shown in purple and gold, respectively.
(C) 2:4 vIL-10/sIL-10R1 complex. The site II interface is located between the cyan/green and gold/purple 1:2 vIL-10/sIL-10R1 complexes.
Residues that form the putative IL-10R2 binding site (Figure 6) are shown on the vIL-10s in space filling representation. IL-10R2 binding sites
are colored green if they are accessible to the IL-10R2 chain or red if the site is occluded in the site II interface.to the previously determined structure of free hIL-10, g
Aproviding little insight into how vIL-10 manipulates re-
ceptor-ligand interactions (Zdanov et al., 1997). The b
(crystal structure of the hIL-10/sIL-10R1 complex also
failed to reveal the molecular basis for the poor binding e
caffinity of vIL-10 to IL-10R1 (Josephson et al., 2001a).
Analysis of vIL-10/hIL-10 chimeras implicated a sin- vle amino acid change at position 87 (I87 in hIL-10 and
87 in vIL-10) for the observed differences in receptor
inding and biological properties of hIL-10 and vIL-10
Ding et al., 2000). The vIL-10 A87I mutant (vIL-10A87I)
xhibited “hIL-10-like” receptor binding properties and
ould induce mast cell proliferation, like hIL-10, while
IL-10 could not (Ding et al., 2000). While interesting,
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not be infected by EBV, casting doubt on the relevance
of the data to the human receptor system. Thus, addi-
tional structural and receptor binding studies between
vIL-10A87I and human IL-10R1 are warranted to further
define the molecular basis of vIL-10’s low affinity for
the IL-10R1 chain.
In this study, we have determined crystal structures
of vIL-10 and vIL-10A87I bound to a soluble fragment of
IL-10R1 (sIL-10R1). Comparison of vIL-10/sIL-10R1 and
hIL-10/sIL-10R1 complexes reveals that vIL-10 un-
dergoes several subtle structural changes that modu-
late its affinity for sIL-10R1. In particular, the AB and
CD loops of vIL-10 exhibit increased disorder/mobility
in the vIL-10/sIL-10R1 complex relative to the hIL-10/
sIL-10R1 structure. In addition, the domains of vIL-10
are rotated by 4° on the surface of sIL-10R1, which sub-
tly alters contacts in the site I interface. Finally, vIL-10
exhibits an 8° larger interdomain angle than hIL-10. The
same regions exhibit the largest structural differences
in comparisons between cmvIL-10/sIL-10R1 and hIL-
10/sIL-10R1 complexes, emphasizing their importance
for manipulating viral IL-10 cell signaling. Isothermal ti-
tration calorimetry (ITC) experiments show that a single
domain of vIL-10 (vIL-10M1) exhibits a 173-fold higher
dissociation constant for sIL-10R1 (Kd = 173 nM) than
hIL-10 (hIL-10M1, Kd = 1 nM). In addition, the apparent
affinities of soluble IL-10R2 (sIL-10R2) for the hIL-10/
sIL-10R1 (Kd = 234 M), vIL-10/sIL-10R1 (Kd = 279 M),
and cmvIL-10/sIL-10R1 (Kd = 77 M) binary complexes
were defined. Together, these studies suggest that
structural changes in the AB/CD loop region and the
orientation of vIL-10 on the surface of IL-10R1 are the
principal mediators of vIL-10’s affinity for IL-10R1 but
have little or no impact on IL-10R2 binding. In contrast,
cmvIL-10 has retained essentially “hIL-10-like” affinity
for IL-10R1 and also exhibits a higher affinity for the
IL-10R2 chain than hIL-10 or vIL-10. The data provide
insights into how subtle changes in vIL-10/sIL-10R1
disrupt IL-10R1 binding, while larger structural changes
in cmvIL-10/sIL-10R1 complex appear to target the IL-
10R2 interaction. These differences have profound
functional significance in shaping IL-10 modulated host
immune responses to invading pathogens.
Results and Discussion
Structure Determination and Quality of the Models
vIL-10 and vIL-10A87I were overexpressed in E. coli and
purified using protocols previously described for hIL-10
(Josephson et al., 2000b). sIL-10R1 was expressed in
insect cells and purified from the culture media as de-
scribed (Josephson et al., 2001b). vIL-10 or vIL-10A87I
was mixed with sIL-10R1 (1:2 ratio), purified by gel
filtration chromatography, and crystallized from PEG-
6000 solutions. Crystals for each complex belong to the
space group P3212 with cell constants similar to the
hIL-10/sIL-10R1 complex (Table 1; Josephson et al.,
2001b). The asymmetric units contain one polypeptide
chain of vIL-10 or vIL-10A87I and one molecule of sIL-
10R1 corresponding to solvent contents of w46% for
both complexes.
The structure of sIL-10R1 bound to seleno-methio-nine (Se-Met) containing vIL-10A87I was solved by MAD
phasing and refined at 2.7 Å resolution against remote
wavelength data to Rcryst = 20.62% and Rfree = 27.11%
(Table 1). vIL-10 and vIL-10A87I are numbered according
to the hIL-10 sequence as shown in Figure 1. The final
model of vIL-10A87I/sIL-10R1 contains residues 12–157
for vIL-10A87I, residues 2–203 for sIL-10R1, and 41
water molecules. Side chain electron density was not
observed for E46 in the vIL-10A87I/sIL-10R1 crystals.
The overall stereochemistry of the model is very good
with all residues falling in the most favored or addition-
ally favored regions of the Ramachandran plot.
The structure of vIL-10/sIL-10R1 was determined by
molecular replacement using the final vIL-10A87I/sIL-
10R1 structure and refined at 2.8 Å resolution to Rcryst =
26.06% and Rfree = 31.46% (Table 1). The final vIL-10/
sIL-10R1 model contains residues 12–157 for vIL-10,
residues 3–206 for sIL-10R1, and 14 water molecules.
The Wilson B-factor for the vIL-10/sIL-10R1 crystals is
higher (84 Å2) than observed for vIL-10A87I/sIL-10R1
crystals (56.8 Å2). The high R-factors for the vIL-10/sIL-
10R1 structure are at least partly due to increased dis-
order in the entire vIL-10/sIL-10R1 lattice compared to
the hIL-10/sIL-10R1 and vIL-10A87I/sIL-10R1 crystals. In
addition, electron density was not observed for 11 vIL-
10 side chains (D17, K40, D41, E42, K57, Q79, E81, D84,
K125, K130, and K134) and 7 sIL-10R1 side chains
(I113, K121, K128, Q168, L171, K199, and L205). Coor-
dinate errors for the hIL-10 (PDB entry, 1Y6K, 0.42 Å),
vIL-10 (0.64Å), and vIL-10A87I (0.43 Å) receptor com-
plexes were estimated in CNS version 1.1 using the
method of Luzatti and the respective Rfree datasets
(Brunger et al., 1998).
The vIL-10/sIL-10R1 Complex
vIL-10 exists in the crystal as a dimer positioned on a
crystallographic 2-fold axis. Two sIL-10R1s bind the
2-fold related surfaces of vIL-10 comprising helix A, the
AB loop, and helix F (site I interface, Figure 1B) to form
a 1:2 vIL-10/sIL-10R1 complex as previously described
for the hIL-10/sIL-10R1 complex (Josephson et al.,
2001a). The same overall structure is observed for the
vIL-10A87I/sIL-10R1 complex. As previously described
for hIL-10 and cmvIL-10, the C-terminal ends of the
2-fold related sIL-10R1s in the vIL-10 and vIL-10A87I
complexes are separated by w100 Å at the point where
they enter the cell membrane (Jones et al., 2002; Jo-
sephson et al., 2001a).
Size exclusion chromatography on vIL-10/sIL-10R1
and vIL-10A87I/sIL-10R1 complexes suggests they con-
sist of two IL-10 dimers and four sIL-10R1s as pre-
viously described for hIL-10 (Hoover et al., 1999; Jo-
sephson et al., 2000b; Tan et al., 1995). vIL-10/sIL-10R1
and vIL-10A87I/sIL-10R1 2:4 complexes adopt the same
overall structure observed for the hIL-10/sIL-10R1
complex (Figure 1C). The 2:4 solution stoichiometry is
formed in the crystals by adjacent 1:2 vIL-10/sIL-10R1
complexes separated by one unit cell translation of
about 47 Å. Adjacent 1:2 complexes generate a second
interface (site II interface, Figure 1C) between the
N-terminal domain of sIL-10R1 (D1) from one complex
with IL-10 and the C-terminal domain of sIL-10R1 (D2)
from the other. Formation of the site II interface for hIL-
Structure
554Table 1. Data Collection, MAD Phasing, and Refinement Statistics
Data Collection vIL-10A87I/sIL-10R1 vIL-10/sIL-10R1
Se (remote) Se (inflection) Native
Space group P3212 P3212
Wavelength (Å) 0.9252 0.9794 0.9184
Resolution (Å) 60.0–2.7 60.0–2.7 25.0–2.8
No. observations 45,279 32,236 85,877
No. unique 10,500 9,232 9,518
Redundancy 4.3 3.5 9.0
Percent completea 97.6 (85.1) 85.8 (32.9) 96.4 (85.3)
Rsyma,b 0.059 (0.245) 0.057 (0.155) 0.049 (0.173)
Cell a,b (Å) 45.60 47.12
c (Å) 310.61 300.71
MAD Phasing
Resolution (Å) 60.0–2.7
Anomalous scatterers 5 Se atoms
Anomalous phasing power 1.4 1.5
Mean Figure of Merit
After SOLVE run 0.46
After RESOLVE run 0.63
Refinement Statistics
Resolution (Å) 25.0–2.7 25.0–2.8
No. of Reflections Rcryst (Rfree) 9,502 (739) 8,575 (663)
Rcryst (Rfree)c 20.62 (27.11) 26.06 (31.46)
Rmsd bonds (Å)d 0.007 0.009
Rmsd angles (°)d 1.33 1.51
B average (Å2) 43.0 75.6
No. protein atoms 2801 2,751
No. water molecules 41 14
Ramachandran plot quality (%)
Most favored 83.7 75.8
Additionally favored 15.7 23.2
Generously allowed 0.6 0.6
Disallowed 0.0 0.3
a Parentheses denote statistics in the highest resolution shells. They are (2.8–2.7 Å) for vIL-10/sIL-10R1 and (2.9–2.8 Å) for vIL-10A87I/sIL-10R1.
b Rsym = (SrI(i) − <I(h)>r)/(SI(i)), where I(i) is the ith observation of the intensity of a reflection with indices (h, k, l) and <I(h)> is the average
intensity of all symmetry equivalent measurements of that reflection.
c Rcryst = S|Fobs(h) − Fcalc(h)|/S|Fobs(h)|, where Fobs(h) and Fcalc(h) are the observed and calculated structure factor amplitudes, respectively.
d Rmsds in bond lengths and angles are the deviations from ideal values.10, IL-10A87I, and vIL-10 complexes buries 633 Å2, p
t571 Å2, and 481Å2 of surface area, respectively.
(
lStructure of vIL-10
vIL-10 bound to sIL-10R1 adopts the same L-shaped t
wdimer topology observed for unbound vIL-10. (Figure
2). hIL-10 and vIL-10 crystal structures can be divided o
tinto two groups according to the angle between the
domains. The w97° interdomain angle for vIL-10 bound m
tto sIL-10R1 is similar to the interdomain angles of free
vIL-10 (95°; PDB code, 1VLK) and free hIL-10 (96°; PDB C
acode, 1INR) structures (Walter and Nagabhushan, 1995;
Zdanov et al., 1997). However, sIL-10R1 bound vIL- d
(10A87I (89°) and hIL-10 (89°; PDB code, 1Y6K) as well
as another free hIL-10 structure (88°; PDB code, 2ILK), d
twhich forms sIL-10R1-like crystal contacts (Zdanov et
al., 1997), exhibit w8°–11° smaller interdomain angles. v
2The increased interdomain angle of vIL-10 is accompa-
nied by a 4° rotation of each vIL-10 domain on the sur- t
1face of IL-10R1 (Figure 2). This rotation subtly alters
contact distances in the site 1 interface and may be (
partly responsible for the poor affinity of vIL-10 for IL-
10R1 (Table 2). S
sThe domain structures of vIL-10, vIL-10 , and hIL-A87I
10 bound to sIL-10R1 are similar. Each domain is com-osed of four α helices (A, B, C, and D) from one pep-
ide chain and two α helices, E and F, from the other
Figure 1B). The helices are connected by a series of
oops denoted by the helices they join. The most dis-
inct feature of the domains is a 50° bend in helix F,
hich together with the AB loop forms a major portion
f the sIL-10R1 binding site. The greatest difference be-
ween vIL-10 and hIL-10 structures occurs at the N ter-
inus preceding N18. This region connects helix A to
he DE loop via a disulfide bond between C12 and
108. The distance between the structurally conserved
mino acids, C108 and N18, is spanned by two resi-
ues in vIL-10 (C12 and D17) and six residues in hIL-10
C12, T13, H14, F15, P16, and G17) resulting in >4 Å
ifferences in the positions of the Cα atoms. Despite
hese differences, the N-terminal residues of hIL-10 and
IL-10 do not modulate biological activity (Ding et al.,
000; S.Y and M.R.W., unpublished data). Excluding
hese N-terminal residues, receptor bound vIL-10, vIL-
0A87I, and hIL-10 superimpose with root mean square
rms) deviations of 0.48–0.57 Å.
tructure of sIL-10R1
IL-10R1 chains bound to vIL-10, vIL-10 , and hIL-10A87I
all adopt the same rigid structure with an interdomain
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Angles
(A) hIL-10, (B) vIL-10, and (C) cmvIL-10 dimers bound to sIL-10R1
are shown. The interdomain angles of each IL-10 are shown at the
top of each complex. The rotations (in degrees) of each IL-10 do-
main on the surface of sIL-10R1 are denoted by arrows where the
movement is from the circle to the arrowhead. For cmvIL-10/sIL-
10R1 complex, the rotation of each sIL-10R1 relative to the hIL-10/
sIL-10R1 complex is also shown.angle of w92° between the tandem fibronectin type III
(FBN-III) domains (Figure 2). The N-terminal D1 (resi-
dues 1-103) and membrane proximal D2 (residues 104–
205) FBN-III domains are connected by one turn of 310-
helix, a short β strand, and a random coil. The topology
of each domain is a β sandwich containing two antipar-
allel β sheets, composed of β strands A, B, E and G, F,
C, C#. The IL-10 binding site is located at the interface
between the D1 and D2 domains. The rms deviation be-
tween the sIL-10R1 chains in each complex is w0.55 Å.
The vIL-10/sIL-10R1 Site I interface
vIL-10/sIL-10R1, vIL-10A87I/sIL-10R1, and hIL-10/sIL-
10R1 share essentially identical ligand-receptor inter-
faces. As previously described, the structural epitope
consists of IL-10 residues donated from helix A, the AB
loop, and helix F as well as five discontinuous peptide
segments (L2-L6) on sIL-10R1 (Josephson et al., 2001a).
The vIL-10/sIL-10R1 interface consists of 23 vIL-10 res-
idues and 20 sIL-10R1 residues that bury w852 Å2 and
998 Å2 of surface area, respectively. Similar numbers of
residues and amounts of surface area are buried in the
vIL-10 (23, 866Å2)/sIL-10R1 (23, 980 Å2) and hIL-10A87I
(24, 914Å2)/sIL-10R1 (23, 1,017 Å2) complexes (Figure1A). Thus, overall buried surface area does not provide
insight into the differences in affinity and biological ac-
tivity between vIL-10 and hIL-10. Each interface is
highly polar (w75% of the residues) and separated into
two interaction surfaces, site Ia and Ib (Figure 1B). Site
Ia is centered on the bend in helix F and includes the
AB loop, while site Ib is located near the N terminus of
helix A and C terminus of helix F. The ligand binding
loops (L2-L4) of sIL-10R1 interact exclusively with site
Ia, while loops L5 and L6 contact site Ib.
All 12 IL-10 site I amino acids that participate in hy-
drogen bond and/or salt bridge interactions with sIL-
10R1 are conserved in vIL-10, vIL-10A87I, and hIL-10.
Site Ia accounts for approximately two-thirds of the to-
tal buried surface area in the interface and forms nu-
merous salt bridges and hydrogen bonds (Table 2). As
previously described, site Ia interactions are dominated
by three sIL-10R1 residues, Y43, R76, and R96, which
form extensive interactions with vIL-10 residues E142,
Q38, and D144 (Josephson et al., 2001a). Along with
these contacts, the carbonyl oxygens of D44 and N45
in the vIL-10 AB loop participate in hydgrogen bonds
with sIL-10R1 residues G44, and Y43, respectively. The
site Ib interface is smaller. The hydrogen bond/salt
bridge network in Site Ib is formed by S190 and R191
on sIL-10R1 and E151 and R27 on vIL-10. Additional
hydrophobic contacts in the interface consist of sIL-
10R1 residue F143 and vIL-10 residues F19, P20, and
the aliphatic methylene groups of R24 and R27.
Orientation of vIL-10, vIL-10A87I, and hIL-10
Bound to sIL-10R1
vIL-10 exhibits an 8° larger interdomain angle than hIL-
10 (97° versus 89°). In addition to the increased interdo-
main angle, the orientation of each vIL-10 domain is
rotated on the surface of sIL-10R1 by approximately 4°
(Figure 2). Relative to hIL-10/sIL-10R1, the rotation axis
in the vIL-10/sIL-10R1 structure is centered near the
bend in helix F, where it intersects the AB loop on one
end of the helix bundle. This rotation moves the C-ter-
minal end of helix F (residues 151–155, site Ib) away
from sIL-10R1 by w1.4 Å relative to the vIL-10A87I/sIL-
10R1 and hIL-10/sIL-10R1 complexes.
Despite the orientation change, most interatom dis-
tances in site Ia are unchanged between the vIL-10/sIL-
10R1, vIL-10A87I/sIL-10R1, and hIL-10/sIL-10R1 com-
plexes (Table 2). Only 1 of 12 contacts differs by more
than 0.6 Å in the site Ia interfaces of all three com-
plexes. However, as a consequence of the movement
of helix F, four of the nine potential interactions in site
Ib of vIL-10/sIL-10R1 differ from the vIL-10A87I/sIL-10R1
and hIL-10/sIL-10R1 complexes by 0.6–1.8 Å. The con-
served contact distances in site Ia are consistent with
the pivot point of the orientation change being centered
in the site Ia interface. The orientation change also sub-
tly reduces the buried surface area of helix F residues
(Y149, E151, and T155) by 54 Å2 compared to hIL-10/
sIL-10R1 and 37 Å2 compared to vIL-10A87I/sIL-10R1
(Figure 1).
Dynamic Properties of vIL-10 in the sIL-10R1
Bound State
In the absence of crystal contacts, AB loop residues
38–44 are disordered in the crystal structure of un-
Structure
556Table 2. Potential Hydrogen Bonds and Salt Bridges
Receptor Ligand Distance (Å)
Residue Atom Residue Atom hIL-10/R1 vIL-10A87I/R1 vIL-10/R1
Tyr43 OH Asn45 O 3.4 3.3 3.4
OH Lys138 Nζ 2.7 3.1 2.9
OH Glu142 O2 2.8 2.8 2.7
Gly44 N Asp44 O 2.8 3.3 3.2
Arg76 NH1 Gln38 O 3.6 3.3 3.3
NH2 Gln38 O 2.4a 2.4a 3.2a
Arg96 N Gln38 O1 2.6 3.0 2.9
NH1 Ser141 O 3.3 3.3 3.4
NH1 Gln38 N2 3.5 3.2 3.5
NH2 Asp144 Oδ1 2.9 2.7 2.4
NH2 Asp144 Oδ2 2.9 2.6 2.8
Glu101 O2 Lys34 Nζ 3.9 3.7 3.3
Ser190 Oγ Glu151 O2 3.2a 3.4a 4.3a
O Arg24 N 3.1 3.4 3.4
O Arg27 N 3.1 3.1 2.9
O Arg27 NH2 4.5a 4.5a 3.1a
Arg191 NH1 Glu151 O1 3.3a 3.5a 4.2a
NH1 Glu151 O2 3.7 3.4 3.4
NH2 Glu151 O1 3.7a 3.1a 4.9a
O Arg24 N 2.8 3.0 3.0
O Arg24 NH2 3.3a 3.3a 3.9a
Contacts in site Ia and Ib are distinguished by the horizontal line in the table. R1 denotes sIL-10R1. hIL-10/sIL-10R1 distances from PDB
code 1Y6K.
a Denotes distance differences R0.6 Å between any of the three complexes.bound hIL-10 (Figure 3). However, the loop forms w
Eextensive contacts with sIL-10R1, resulting in a well-
ordered turn of helix (residues 38–40) followed by an c
textended structure (residues 41–44) in the IL-10/sIL-
10R1 complex (Figures 3 and 4). Q38, at the N terminus F
oof the loop, hydrogen bonds to sIL-10R1 residues R76
and R96. On the C-terminal end of the loop, the car- t
dbonyl oxygen of D44 forms a main chain hydrogen
bond with G44 from sIL-10R1. The center of the loop i
(residues 39–43) surrounds sIL-10R1 residue Y43, The disorder-order transition that occurs upon hIL-10
Figure 3. Conformational Changes and Rela-
tive B Factor Plot for the Human and Viral
IL-10s
(A) Ribbon diagram of unbound hIL-10 (1INR)
colored purple and sIL-10R1 bound hIL-10
(1Y6K) colored green. The side chains of F36
and F37 are shown for unbound hIL-10 (gray)
and F36, F37, and Q38 for sIL-10R1 bound
hIL-10 (white). Residues 38–44 are not ob-
served in the structure of unbound hIL-10
(1INR), and are represented by red spheres.
I87 is shown as a space filling model in yel-
low. The structural features of unbound vIL-
10 (1VLK, not shown) and unbound hIL-10
(1INR) are very similar including the confor-
mation of F36 and F37 (gray).
(B) B factor difference plot (Relative B) for
hIL-10 (green), vIL-10 (black), vIL-10A87I
(cyan), and cmvIL-10 (purple) bound to sIL-
10R1. Relative B corresponds to the differ-
ences between the residue B factor and the
average B factor. The secondary structure of
IL-10 is shown at the bottom of the plot. He-
lical segments are shown as boxes and the
loop regions as lines. Residues that contact
sIL-10R1 are colored red, others in yellow.hich forms additional contacts with IL-10 residues
142 and K138. In addition to the AB loop itself, adja-
ent residues F36 and F37 adopt different conforma-
ions in bound and unbound IL-10 structures (Figure 3).
36 and F37 pack against I87 located on the CD loop
f hIL-10 (Figure 3A). This provides a structural link be-
ween conformational changes in the AB loop and resi-
ue 87, which is an isoleucine in hIL-10 and an alanine
n vIL-10.
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pleted in the vIL-10/sIL-10R1 complex. In the vIL-10/
sIL-10R1 complex, F36 and F37 move w1.3 Å (relative
to hIL-10) toward A87 located on the CD loop of the
molecule (Figure 4A). This movement maximizes the
packing of the vIL-10 hydrophobic core, which has lost
w69 Å2 of hydrophobic side chain surface area due to
an alanine in vIL-10 versus an isoleucine in hIL-10. The
movement of F36 and F37 increases the distance be-
tween the carbonyl oxygen of Phe-36 and the nitrogen
of Lys-40 from 3.0 Å in hIL-10 to 4.3 Å in vIL-10. This
disrupts the α-helical hydrogen bonding of helix A re-
sulting in a distorted β-turn structure for residues 35–
38. These structural changes are correlated with an in-
crease in disorder of the vIL-10 AB loop as evidenced
by high B factors and the lack of side chain electron
density for AB loop residues K40, D41, and E42.
To provide a more quantitative analysis of the dy-
namic properties of the human and viral IL-10s in com-
plex with sIL-10R1, relative B factors were compared
for each structure (Figure 3B). In this analysis, residues
on helix A and helix F, which contact sIL-10R1, have
the smallest relative B factors in both the human and
viral IL-10 receptor complexes. The largest relative B
factors are observed for the CD loop of vIL-10, which
contains the A87 substitution. For IL-10 residues that
contact sIL-10R1, the greatest differences in relative B
factors occurs between the AB loops of hIL-10 and vIL-
10. AB loop residues 38–44 of hIL-10 exhibit the small-
est relative B factors and vIL-10 the largest (Figure 4C).
Relative B factor values for the vIL-10A87I AB loop are
intermediate between hIL-10 and vIL-10. The region of
the vIL-10A87I loop that contains vIL-10 amino acids
E42 and V43 (residues 42–44) exhibits relative B factors
considerably larger than hIL-10. In contrast, vIL-10A87I
residues 38–41, which pack against I87, exhibit relative
B factors essentially identical to hIL-10. Thus, the in-
creased disorder/mobility of the AB/CD loops occursFigure 4. The AB/CD Loop Region of Human
and Viral IL-10s Bound to sIL-10R1
(A) Residues 36–44 and 87 are shown for
hIL-10 (cyan ribbon) and vIL-10 (ribbon col-
ored by relative B factors). For the vIL-10 rib-
bon, relative B factors < 5 are cyan, green
if R 5 but < 10, yellow if R 10 but < 20, or-
ange if R 20 but < 30, and red if R 30. Side
chains for hIL-10 are white and gray for vIL-
10. sIL-10R1 residues that contact hIL-10 are
green and yellow if they contact vIL-10. Oxy-
gen atoms are colored red and nitrogen
atoms blue.
(B) Comparison between hIL-10 and cmvIL-
10 AB and CD loop regions. Color coding is
as described in (A).
(C) Close-up of the relative B factor plot in
Figure 3B for the AB loop region. Color cod-
ing of the chart is described in the legend for
Figure 3.in areas with vIL-10 amino acid substitutions and mayreflect weakened or suboptimal interactions with sIL-
10R1.
Thermodynamic Studies on hIL-10 and vIL-10s
The interaction between sIL-10R1 and hIL-10, vIL-10,
and vIL-10A87I monomers were characterized by iso-
thermal titration calorimetry (ITC, Figure 5). Monomeric
IL-10s (hIL-10M1, vIL-10A87IM1, and vIL-10M1) were
used for these studies because they form 1:1 interac-
tions with sIL-10R1 (Josephson et al., 2000a). Binding
data collected with IL-10M1s specifically addresses the
affinity of the site I interface (Figure 1B) and avoids un-
certainties in the contribution of multiple site I or site II
interactions that occur upon 2:4 complex formation by
the IL-10 dimers (Figure 1C).
ITC analysis on hIL-10M1/sIL-10R1, vIL-10A87IM1/
sIL-10R1, and vIL-10M1/sIL-10R1 complexes reveal
dissociation constants of 1 nM, 27 nM, and 173 nM,
respectively (Figure 5). The data confirm that the site I
interface between hIL-10 and sIL-10R1 is very strong
(Kd = 1 nM), while the site I interface of vIL-10/sIL-10R1
is approximately 173-fold weaker (Kd = 173 nM). Previ-
ous binding studies, using solution affinity methods,
suggested the apparent dissociation constants for hIL-
10/sIL-10R1 (Kd = 8 nM) and vIL-10/sIL-10R1 (Kd = 130
nM) interactions differed by only about 20-fold (Table
3). However, the ITC data reported in Figure 5 (Kd = 1
nM) and the kinetic analysis (Kd = 0.7 nM, Kon = 3.5 ×
105 M−1 s−1, Koff = 2.6 × 10−4 s−1) performed by Logsdon
et al., 2002 suggest the previously determined Kd for
the hIL-10/sIL-10R1 interaction (Kd = 8 nM) is about 10-
fold too high (Table 3). This correction is important be-
cause the w170-fold affinity difference between hIL-
10M1 and vIL-10M1 accounts for most (all but w6-fold)
of the 1000-fold difference in affinity observed between
hIL-10 and vIL-10 dimers on human cells. Thus, a single
site I interface contributes most of the binding energy
for the hIL-10/sIL-10R1 and vIL-10/sIL10R1 complexes.Replacing the alanine at position 87 in vIL-10M1 with
Structure
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The top panels show the raw heat pulse data and the bottom panels contain the binding isotherm obtained by plotting integrated heat per
mole of injectant (sIL-10R1) against the molar ratio of sIL-10R1 to the total concentration of ligand in the cell. The line through the boxes
represents the best least squares fit of the data to a one-site binding model. The resulting binding parameters obtained for each experiment
are shown in the figure. The units for G, H, and –TS are kcal mol−1.an isoleucine (vIL-10A87IM1) results in only an w6-fold
1increase in sIL-10R1 affinity (Kd = 27 nM) compared to
vIL-10M1 (Kd = 173 nM). Thus, in contrast to previous t
Fbinding studies with vIL-10A87I on murine cells express-
ing murine IL-10 receptors (Ding et al., 2000), vIL- w
h10A87IM1 binds to human sIL-10R1 with an affinity (Kd =
27 nM) closer to vIL-10M1 (Kd = 173 nM) than hIL-10M1 2
1(Kd = 1 nM). Consistent with our binding data, vIL-10
and vIL-10A87I exhibit similar biological activities on e
tcells expressing human IL-10 receptors (S.I.Y. and
M.R.W., unpublished data). This suggests the reported c
aw100-fold increase in IL-10R1 affinity and “human IL-
10-like” biological properties of vIL-10A87I are specific i
2to murine cells, but do not reflect its receptor binding or
biological activity on human cells, which EBV naturally
infects. Structural comparisons between the human C
Iand viral IL-10/sIL-10R1 complexes suggest most of
the remaining difference in binding energy is contrib- q
auted by hIL-10 residues at the C-terminal end of the AB
loop and residues in the site Ib interface. Structural analyses reveal the domains of cmvIL-10 are
Table 3. Binding Constants (Kd) for IL-10/sIL-10R1 Interactions
Method hIL-10 vIL-10 vIL-10A87I cmvIL-10
SPR-SAa 8 nM 130 nM 25 nMb 4 nM
ITCc,d,e 1 nM 173 nM 27 nM —
SPRc,f 0.7 nM — — —
a SPR-SA, apparent Kd’s obtained by surface plasmon resonance solution affinity methods using human and viral IL-10 dimers as described
by Jones et al. (2002). The underlined Kd for hIL-10 is inconsistent with SPR (Logsdon et al., 2002) and ITC data, using IL-10 monomers,
completed in this study (Figure 5).
b Unpublished SPR-SA data performed as described in (a).
c Binding constants obtained using human or viral IL-10 monomers interacting with sIL-10R1.
d ITC experiments performed in this study (Figure 5).
e Previous ITC experiments using 8 or 12 injections yielded inaccurate Kd’s of 30 nM and 8 nM for the hIL-10M1/sIL-10R1 interaction
(Josephson et al., 2000b, 2002).
f Kinetic analysis of the hIL-10M1/sIL-10R1 interaction using SPR as described by Logsdon et al., 2002. Kon and Koff values for the interaction
are 3.5 × 105 M−1 s−1 and 2.6 × 10−4 s−1, respectively.Certainly, differences in the kinetics of hIL-10/sIL-
0R1 and vIL-10/sIL-10R1 interactions play an impor-
ant role in how they induce their biological activities.
or example, hIL-10M1 forms a very stable complex
ith sIL-10R1 (Koff = 2.6 × 10−4 s−1) corresponding to a
alf-life (t1/2) of approximately 45 min (Logsdon et al.,
002). Assuming a similar on-rate for hIL-10 and vIL-
0, the off-rate of the vIL-10M1/sIL-10R1 interaction is
stimated to be w5 × 10−2 s−1, which corresponds to a
1/2 of about 14 s. The structure of the vIL-10/sIL-10R1
omplex is consistent with the transient nature of the
ssociation and the inability of vIL-10 to initiate signal-
ng on cells with very low IL-10R1 levels (Ding et al.,
001).
omparisons with the cmvIL-10/sIL-10R1 Complex
n contrast to vIL10, cmvIL-10 exhibits only 27% se-
uence identity with hIL-10, yet binds to sIL-10R1 with
n affinity very similar to hIL-10 (Jones et al., 2002).
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10A87I (rmsd w0.5 Å). However, cmvIL-10 has success-
fully mimicked the structure and many of the same con-
tacts observed in the hIL-10/sIL-10R1 site I interface
(Jones et al., 2002). A total of 25 cmvIL-10 and 21 sIL-
10R1 residues bury 945 Å2 and 1,007 Å2 of surface area
into the site I interface, respectively.
The largest structural differences between cmvIL-10/
sIL-10R1 and hIL-10/sIL-10R1 complexes occur in the
same regions (AB/CD loop, orientation change, interdo-
main angle) previously identified for the vIL-10/sIL-
10R1 complex. However, because of the lower sequence
identity, the structural changes are more pronounced in
cmvIL-10/sIL-10R1 than vIL-10/sIL-10R1. For example,
cmvIL-10 exhibits a 130° interdomain angle that is
w40° larger than the interdomain angles of hIL-10 (89°)
or vIL-10 (97°). The increased interdomain angle of
cmvIL-10 rotates each sIL-10R1 by w25°, relative to
the hIL-10/sIL-10R1 complex, toward the putative posi-
tion of the cell membrane (Figure 2). As observed for
vIL-10, each domain of cmvIL-10 also undergoes a
small (5°) rotation on the surface of sIL-10R1. However,
the rotation of cmvIL-10 is in the opposite direction
from that observed for vIL-10 (Figure 2). In contrast to
the vIL-10/sIL-10R1 structure, the 5° rotation of cmvIL-
10 does not disrupt the number of contacts or the
amount of buried surface area in the cmvIL-10/sIL-
10R1 site I interface when compared to hIL-10/sIL-
10R1.
As observed for vIL-10, the greatest change in the
site I interface between hIL-10/sIL-10R1 and cmvIL-10/
sIL-10R1 occurs in the AB loop (Figure 4B). The AB
loop in cmvIL-10 is one residue shorter than in hIL-10
and vIL-10 (hIL-10/vIL-10 residue K40 is deleted in
cmvIL-10), which subtly changes its conformation (Fig-
ure 4B). The conformational change occludes Y43 in
sIL-10R1 from inserting itself underneath the cmvIL-10
AB loop, as observed in hIL-10/sIL-10R1 and vIL-10/
sIL-10R1 complexes. Instead, the side chain of Y43 ro-
tates by w40° where it hydrogen bonds to sIL-10R1
residue R76. As a result, the central portion of the loop
loses considerable hydrogen bond and van der Waals
interactions with Y43. This may explain why the AB
loop of cmvIL-10 and vIL-10 exhibit approximately the
same relative B factor values when bound to sIL-10R1
(Figure 4). Based on the analysis of vIL-10, the larger
B factor values for the cmvIL-10 AB loop likely reflect
disrupted interactions with sIL-10R1. However, in con-
trast to vIL-10, the remaining contacts in the cmvIL-10
site I interface, especially in site Ib, do not appear to
be compromised and allow cmvIL-10 to retain “hIL-10-
like” affinity for sIL-10R1.
IL-10R2 Interactions
Recently, we identified the IL-10R2 binding site on IL-
22, a cellular homolog of IL-10, which also requires IL-
10R2 to induce its biological activities (Logsdon et al.,
2004). The IL-10R2 binding hotspot on IL-22 consists
of N54, R55, Y114, and E117 located on helices A and
D. Based on the studies with IL-22, we have mapped
the structurally equivalent residues in the human and
viral IL-10s (Figure 6). The putative IL-10R2 contact res-
idues in hIL-10 and vIL-10 are D25, D28, A29, H90, and
S93. In cmvIL-10, they are D25, V28, T29, E90, and S93.Figure 6. The Putative IL-10R2 Binding Site
The sIL-10R1s from each complex were superimposed. Ribbons
for sIL-10R1 bound to hIL-10 (green), vIL-10 (blue), vIL-10A87I (yel-
low), and cmvIL-10 (purple) are shown. Side chains for the cmvIL-
10 IL-10R2 binding site are red and hIL-10 I87 is shown in gray.Peptide mapping of the IL-10/sIL-10R2 interaction is
consistent with the structural assignment of the IL-
10R2 binding site (Wolk et al., 2004).
In contrast to IL-22, the IL-10R2 chain contributes
essentially no binding energy to hIL-10 or vIL-10 ter-
nary complex (IL-10/IL-10R1/IL-10R2) formation. Sup-
port for this comes from cell binding studies that reveal
hIL-10 and vIL-10 have identical affinity for cell surface
IL-10R1 in the presence or absence of IL-10R2 (Ding et
al., 2001). This suggests structural differences in the
vIL-10 AB/CD loops, the 4° orientation change of vIL-
10 on sIL-10R1, and the 8° difference in interdomain
angle between hIL-10 and vIL-10 have little or no im-
pact on IL-10R2 binding. Instead, it appears the very
weak IL-10R2 interactions, which ultimately initiate cell
signaling, are regulated by, and dependent on, the long
(w1 hr) or short (w20 s) t1/2 values of the hIL-10/IL-
10R1 and vIL-10/IL-10R1 complexes, respectively.
The strategy used by cmvIL-10 to engage the IL-10
receptors is different from vIL-10. In contrast to vIL-10,
cmvIL-10 has retained an affinity for sIL-10R1 that is
very similar to hIL-10. However, the sequence and
structure of the putative IL-10R2 binding site on cmvIL-
10 is very different from hIL-10 and vIL-10. First, only
two of the five IL-10R2 contact residues in hIL-10 and
vIL-10 are conserved in cmvIL-10. Second, the do-
mains of cmvIL-10 are rotated by 5° on the surface of
sIL-10R1, which changes the position of the IL-10R2
binding site. Finally, the 130° interdomain angle of
cmvIL-10 rotates each sIL-10R1 by 25°, which further
changes the orientation of the IL-10R2 binding site rela-
tive to hIL-10/sIL-10R1 and vIL-10/sIL-10R1 complexes.
These structural changes are expected to significantly
change the geometry and/or the affinity of IL-10R2
chain for the cmvIL-10/sIL-10R1 complex.
The affinity of IL-10R2 for vIL-10/sIL-10R1, hIL-10/
sIL-10R1, and cmvIL-10/sIL-10R1 binary complexes
was determined by an SPR equilibrium binding experi-
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Figure 7. IL-10R2 Interactions with Human and Viral IL-10/sIL- v
10R1 Complexes t
Equilibrium SPR responses (RU), obtained with increasing concen- l
trations (0–700 M) of sIL-10R2 in the presence of a constant con- a
centration (2 M) of sIL-10R1, are plotted (y axis) against sIL-10R2
Fconcentration (x axis) and fit to a 1:1 binding model (line). The con-
cstant RUs contributed by sIL-10R1 binding have been removed
bfrom the RU responses on the plot.
v
c
Iment (Figure 7). hIL-10, vIL-10, and cmvIL-10 were cou-
apled to CM-5 sensor chips using NHS-EDC chemistry.
wTo measure IL-10R2 binding to the IL-10/sIL-10R1 com-
dplexes, solutions containing a constant level of sIL-
s10R1 (2 M) and increasing amounts of sIL-10R2
c(0–700 M) were injected over the human and viral IL-
t10 surfaces. Apparent Kds were obtained by fitting the
cbinding curves to a simple 1:1 binding model. As sug-
gested by the structural comparison, the cmvIL-10/sIL-
b10R1 complex exhibits a higher affinity for sIL-10R2
s(Kd = 77 M ± 7) than either vIL-10/sIL-10R1 (Kd = 279
sM ± 70) or hIL-10/sIL-10R1 (Kd = 234 M ± 61) com-
rplexes. Interestingly, cmvIL-10, vIL-10, and hIL-10 all
sbound equivalent amounts of sIL-10R1, but the cmvIL-
h10/sIL-10R1 complex bound approximately three to five
otimes as much IL-10R2 as the hIL-10/sIL-10R1 and vIL-
410/sIL-10R1 complexes. These data suggest cmvIL-10
nexhibits a higher affinity for IL-10R2 and the geometry
cof the cmvIL-10/sIL-10R1 complex may increase the
iaccessibility of the IL-10R2 chain to the IL-10R2 bind-
ring site.
i
2
The IL-10/sIL-10R1 2:4 Complex d
The identification of a putative IL-10R2 binding site on o
IL-10 allows us to reevaluate the role of the IL-10/sIL- t
10R1 2:4 complex in human and viral IL-10 signaling. R
Based on sequence similarity between IL-10R1 and IL- v
10R2, we previously proposed the 2:4 complex may a
mimic the biologically active IL-10/IL-10R1/IL-10R2 cell a
surface complex (Josephson et al., 2001a). However, i
the location of the putative IL-10R2 binding site on IL- b
10 suggests that the 2:4 complex may actually antago- s
nize IL-10 activity by blocking the IL-10R2 chain from o
the IL-10R2 binding site (Figure 1C). The elution profiles a
of vIL-10/sIL-10R1, vIL-10A87I/sIL-10R1, and cmvIL-10/ t
sIL-10R1 complexes from size exclusion columns are t
similar to the 2:4 hIL-10/sIL-10R1 complex, suggesting b
cthe viral IL-10s also form 2:4 complexes in solution.owever, in contrast to the vIL-10/sIL-10R1 and vIL-
0A87I/sIL-10R1 structures, crystals of the cmvIL-10/
IL-10R1 complex do not contain the 2:4 complex
Jones et al., 2002). Furthermore, modeling studies re-
eal that the interdomain angle of cmvIL-10 prevents
mvIL-10/sIL-10R1 from adopting the same 2:4 com-
lex structure observed in the crystals of the hIL-10/
IL-10R1 and vIL-10/sIL-10R1 complexes. As suggested
y our IL-10R2 binding experiments, this structural differ-
nce might increase the accessibility of the IL-10R2 chain
o the IL-10R2 binding site on cmvIL-10/sIL-10R1, relative
o the hIL-10/sIL-10R1 and vIL-10/sIL-10R1 complexes,
nd subsequently increase cmvIL-10’s activity.
onclusions
n this report we have determined crystal structures of
IL-10 and vIL-10A87I bound to sIL-10R1. In contrast to
he free ligand structures, analysis of the receptor-
igand complexes has identified three structural mech-
nisms that modulate vIL-10’s affinity for sIL-10R1.
irst, the AB and CD loops of vIL-10 undergo subtle
hanges in their structures and dynamics on sIL-10R1
inding (Figures 3 and 4). Second, the orientation of
IL-10 on sIL-10R1 differs by 4° from hIL-10, which in-
reases vIL-10/sIL-10R1 contact distances in the site
b interface (Figure 2). Third, vIL-10 bound to sIL-10R1
dopts an interdomain angle of w97° compared to
89° for the hIL-10/sIL-10R1 complex. Although these
ifferences are small, they are likely very important,
ince similar structural changes are observed in the
mvIL-10/sIL-10R1 complex. The major question from
he structural studies is what is the contribution of each
hange to receptor binding and biological activity?
ITC binding experiments emphasize the large contri-
ution a single domain of hIL-10 or vIL-10 makes to
IL-10R1 affinity. This suggests structural changes as-
ociated with the site I interface are most important for
educing vIL-10’s affinity for sIL-10R1. The largest
tructural change between the domains of vIL-10 and
IL-10 is an w1.3 Å movement of F36 and F37, located
n helix A, toward A87 in the CD loop of vIL-10 (Figure
). This difference causes subtle structural and dy-
amic changes in the AB and CD loops. While the
hanges appear too small to induce large differences
n affinity, the structure of the hIL-10/sIL-10R1 complex
eveals precise geometrical positioning of the AB loop
s required for high-affinity binding (Josephson et al.,
001a), in particular, the main chain–main chain hy-
rogen bond between IL-10 D44 and sIL-10R1 G44 on
ne end of the loop and the main chain–side chain in-
eractions between IL-10 Q38 and sIL-10R1 R76 and
96 on the other (Figure 4). Amino acid substitutions in
IL-10 appear to disrupt the ability of the AB loop to
dopt the proper geometry required for stable high-
ffinity sIL-10R1 binding. Thus, local disorder observed
n the AB and CD loops may reflect weakened, or su-
optimal, interactions with sIL-10R1. From our crystal
tructure, we cannot distinguish if the observed dis-
rder corresponds to a few discrete conformations
veraged in the crystals, or an ensemble of conforma-
ions. However, either interpretation is consistent with
he importance of the AB/CD loop region in IL-10R1
inding and the negative impact of vIL-10 amino acid
hanges in this region on IL-10R1 binding.
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increased interdomain angle for manipulating sIL-10R1
affinity and biological activity are less clear. In particu-
lar, vIL-10A87I binds to sIL-10R1 with an affinity (Kd = 27
nM) similar to vIL-10 (Kd = 173 nM), yet vIL-10A87I exhib-
its the same orientation on sIL-10R1, and the same in-
terdomain angle, as hIL-10 (Kd = 1 nM) in the hIL-10/
sIL-10R1 complex. This appears to contradict the inter-
pretation of the vIL-10/sIL-10R1 structure. The discrep-
ancy is likely due to crystallization and structure deter-
mination of the Se-Met-vIL-10A87I/sIL-10R1 complex,
rather than the wild-type-vIL-10A87I/sIL-10R1 complex.
Crystals of wild-type-vIL-10A87I/sIL-10R1 exhibit poor
diffraction to w3.8 Å resolution, a Wilson B factor of
104 Å2, and were unsuitable for high-resolution struc-
ture studies.
The crystallographic and ITC binding data suggest
vIL-10A87I exists in at least two conformations that have
been “trapped” in the wild-type-vIL-10A87I/sIL-10R1
and Se-Met-vIL-10A87I/sIL-10R1 crystals. One confor-
mation corresponds to the Se-Met-vIL-10A87I/sIL-10R1
structure, which is similar to hIL-10/sIL-10R1 complex,
while the second conformation resembles the vIL-10/
sIL-10R1 complex. Despite the “hIL-10-like” features of
the Se-Met-vIL-10A87I/sIL-10R1 structure, the relative B
factors at the C-terminal end of the AB loop are larger
than observed in hIL-10 (Figure 4C), which is consistent
with vIL-10 AB loop residues Q42E and L43V disrupt-
ing high-affinity sIL-10R1 contacts in the vIL-10A87I/sIL-
10R1 site I interface.
The combination of binding and structural data on
hIL-10/sIL-10R1, vIL-10/sIL-10R1, and cmvIL-10/sIL-
10R1 complexes provides an emerging picture of how
the viral IL-10s manipulate IL-10 receptor interactions
and biological activity. Cell surface binding studies
show hIL-10 and vIL-10 depend almost entirely on in-
teractions with IL-10R1 for their functional properties.
Our ITC studies, with monomeric IL-10s, show most of
the difference in IL-10R1 binding energy occurs in the
site I interface (Figures 1B and 5). While the subtle
structural differences in vIL-10 lower its affinity for IL-
10R1, they do not appear to alter IL-10R2 affinity. This
is consistent with the conserved IL-10R2 binding sites
on hIL-10 and vIL-10 (Figure 6). Thus, the w1000-fold
difference in IL-10R1 affinity between vIL-10 and hIL-
10 limits vIL-10’s ability to induce biological activity to
cells that express high levels of the IL-10R1 chain, irre-
spective of the IL-10R2 chain density (Ding et al., 2001;
Raftery et al., 2004).
The sequence and structure of cmvIL-10 is markedly
different from hIL-10 and vIL-10. However, the site I
interface in the cmvIL-10/sIL-10R1 complex is essen-
tially identical to the vIL-10/sIL-10R1 and hIL-10/sIL-
10R1 structures. Like vIL-10, the structure of cmvIL-10
bound to sIL-10R1 exhibits a different AB loop confor-
mation (Figure 4B), a different orientation on the surface
of IL-10R1, and a large, rather than small, change in
interdomain angle (Figure 2). However, in contrast to
vIL-10, these changes result in an affinity for IL-10R1
that is similar to hIL-10 (Jones et al., 2002).
Why would cmvIL-10 undergo such a large change in
its structure to conserve high-affinity sIL-10R1 binding,
which is already present in hIL-10? The IL-10R2 bind-
ing experiments suggest changes in the structure ofcmvIL-10 increases its affinity for IL-10R2 and may
change the accessibility of the IL-10R2 binding site to
IL-10R2 (Figures 1C and 7). With an increased affinity
for IL-10R2, cmvIL-10 may be able to induce biological
activities on cells that express IL-10R1 levels below the
threshold required for hIL-10 signaling, or increase the
activity of cmvIL-10, relative to hIL-10 or vIL-10, on a
given cell line. Consistent with the later hypothesis,
cmvIL-10 has recently been shown to induce approxi-
mately twice the amount of phosphorylated STAT3 in
immature dendritic cells as hIL-10 while vIL-10 was to-
tally inactive (Raftery et al., 2004). Further elucidation
of the molecular mechanisms used by the human and
viral IL-10s to manipulate immune responses might be
useful in the design of therapies to control inflammation
and enhance antiviral responses.
Experimental Procedures
Cloning and Mutagenesis
The expression plasmid for vIL-10 was generated by inserting the
vIL-10 gene (pBCRF1, ATCC) into the expression vector pET-32.
vIL-10 DNA was amplified using the forward primer 5#-GCCATATG
CAATGTGACAATTTTCC-3# and the reverse primer 5#-TACTCGAG
TCACCTGGCTTTAATTGTC-3#. The resulting PCR product was di-
gested with NdeI and XhoI followed by ligation into pET-32 to
generate pET-32-vIL-10. Mutagenesis of pET-32-vIL-10 to pET-32-
vIL-10A87I was performed using the QuikChange site-directed mu-
tagenesis kit (Stratagene).
Expression plasmids for vIL-10M1 and vIL-10M1A87I were made
from two DNA fragments amplified using pET-32-vIL-10 or pET-32-
vIL-10A87I as templates. The first DNA fragment corresponding to
vIL-10 or vIL-10A87I residues 1–116 and the insertion peptide se-
quence GGG, was PCR-amplified with the forward primer 5#-ACG
ACTCACTATAGGGGAATTGTG-3# and the reverse primer 5#-ATTG
GATCCACCACCGTTCTCACACGGCAGGAACCTG-3#. The fragment
was then digested with NdeI and BamHI. The second DNA frag-
ment, which codes for insertion peptide SGG and vIL-10 residues
117–159, was amplified with the forward primer 5#-ATTGGATCCG
GTGGTAAGAGTAAAGCTGTGGAACAG-3# and the reverse primer
5#-CCAAGGGGTTATGCTAGTTATTGC-3#, and then digested with
BamHI and XhoI. Expression plasmids, pET-32-vIL-10M1 and pET-
32-vIL-10M1A87I, were obtained by ligating the fragments into
pET-32.
Protein Purification and Complex Preparation
vIL-10, vIL-10A87I, hIL-10, vIL-10M1, vIL-10M1A87I, and hIL-10M1
were overexpressed using E. coli strains BL21 (DE3) or (BL21) Ro-
setta2 (DE3) and purified as previously described (Josephson et al.,
2000b). Se-Met-vIL-10A87I was expressed using B834 (DE3) cells
containing the pET-32-vIL-10A87I plasmid. Cells were grown in M9
minimal media with 100 g/ml racemic Se-Met and vIL-10A87I ex-
pression was induced for 6 hr. Se-Met incorporation was confirmed
by MALDI-TOF mass spectrometry after purification. sIL-10R1,
where all six N-linked glycosylation sites were removed by muta-
tion (sIL-10R1Q6), was expressed in Drosophila S2 cells and puri-
fied by hIL-10 affinity chromatography as previously described (Jo-
sephson et al., 2001a, 2001b). The receptor complexes were
formed by mixing vIL-10 or Se-Met-vIL-10A87I with sIL-10R1Q6 at
the molar ratio of 1:2 for 30 min on ice. The complexes were subse-
quently purified by gel filtration chromatography. cmvIL-10 used in
the SPR assay was expressed and purified as previously described
(Jones et al., 2002). Glycosylated sIL-10R1 was used for ITC and
SPR analyses (Josephson et al., 2001b). sIL-10R2 was expressed in
Drosophila S2 cells and purified by nickel affinity chromatography
followed by ion exchange chromatography as previously described
(Logsdon et al., 2002).
Crystallization and Data Collection
Native crystals of vIL-10/sIL-10R1Q6 or Se-Met-labeled crystals of
vIL-10 /sIL-10R1Q6 were grown at 25°C by hanging drop vaporA87I
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562diffusion. For vIL-10A87I/sIL-10R1Q6 crystallization, 1 l of receptor t
pcomplex at 7.5 mg/ml in 150 mM NaCl and 20 mM Tris-HCl (pH 8.0)
was mixed with 1 l of well solution containing 7% PEG 6000, 4% e
cMPD, 0.1 M MgCl2, and 0.1 M ADA (pH 6.2). The resulting crystals
were crushed and used to streak seed fresh hanging drops that
had equilibrated for 4 hr. vIL-10A87I/sIL-10R1Q6 crystals were cryo- S
protected by stepwise addition of PEG 400 to a final concentration A
of 22%–25% in 9% PEG 6000, 4% MPD, 0.1 M MgCl2, and 0.1 M o
ADA (pH 6.2) and then flash frozen in a cryostream of nitrogen gas t
(100 K). vIL-10/sIL-10R1Q6 crystallization was performed using 2 l
l of receptor complex at 5.0 mg/ml in 150 mM NaCl and 20 mM g
Tris-HCl (pH 8.0) and 2 l of reservoir solution containing 8% PEG 1
6000, 0.1 M MgCl2, and 0.1 M ADA (pH 6.2). The resulting crystals d
were used for streak seeding. vIL-10/sIL-10R1Q6 crystals were 
cryoprotected with 30% PEG 400 in 12% PEG 6000, 0.1 M MgCl2, n
and 0.1 M ADA (pH 6.2) and then flash frozen in a cryostream of p
nitrogen gas (100 K). X-ray diffraction data were collected at the b
Stanford Synchrotron Radiation Laboratory beamline 9-2 equipped i
with an ADSC CCD detector. The data were processed using r
DENZO and SCALEPACK (Otwinowski and Minor, 1997). t
b
sStructure Determination
0The structure of vIL-10A87I/sIL-10R1Q6 was determined using a
ttwo-wavelength MAD experiment performed on Se-Met–incorpo-
rated vIL-10A87I/sIL-10R1Q6 crystals. Five of the six selenium posi-
tions were located and phases calculated using SOLVE (Terwilliger
Aand Berendzen, 1999). The crystal structures of free vIL-10 (1VLK)
and hIL-10 bound sIL-10R1Q6 (1J7V) were docked onto density-
Wmodified MAD electron density map obtained by RESOLVE (Terwil-
wliger, 2000). The structure was refined against the remote wave-
dlength (25.0–2.7 Å) using CNS version 1.0 (Brunger et al., 1998).
rManual rebuilding of the model was performed using O (Jones et
Lal., 1991).
oThe structure of vIL-10/sIL-10R1Q6 was solved by molecular re-
Splacement (CNS version 1.0) using the search model of the refined
gvIL-10A87I/sIL-10R1Q6. The structure was refined using CNS with
data extending to 2.8 Å resolution. Model building was performed
using O (Brunger et al., 1998; Jones et al., 1991). Analysis and com- R
parison of the models were performed using programs bundled in R
the CCP4 program suite (CCP4, 1994). Model stereochemistry was A
determined with PROCHECK (Laskowski et al., 1993). Superposi- P
tions were performed using LSQKAB. Buried surface areas were
calculated with AREAIMOL using a 1.4 Å probe. Contact distances R
and average temperature factors per residue were obtained using
CONTACT and BAVERAGE, respectively. Viral IL-10/sIL-10R1 struc-
Atures were compared against the 2.5 Å resolution hIL-10/sIL-
c10R1Q6 complex structure (PDB code, 1Y6K). Ribbon diagrams,
8secondary structure assignment, and interdomain angles were cal-
Bculated using the RIBBONS program suite (Carson, 1997). R1 inter-
Gdomain angles were calculated as previously described (Deivanay-
Pagam et al., 2000). IL-10 interdomain angles were calculated from
stwo vector sets obtained by averaging six vectors corresponding
Csix α helices in each domain (residues 21–31, 52–56, 61–74, 88–
105, 120–129, and 143–154). C
C
4Isothermal Titration Calorimetry
Thermodynamic analysis of the interaction between sIL-10R1 and C
hIL-10M1, vIL-10M1 or vIL-10M1A87I was carried out using an MCS- C
ITC titration calorimeter (MicroCal, Northampton, MA) at 25°C. Pro- D
tein samples for ITC experiments were exhaustively dialyzed
D
against 10 mM Na2-PIPES and 150 mM NaCl (pH 7.1). Prior to the l
titration experiments, the samples were degassed for 10 min under
a
vacuum. sIL-10R1 (200 M for the vIL-10M1 experiment, 100 M
c
for the vIL-10M1A87I experiment, and 63 M for hIL-10M1 experi-
dment) in a 250 l injection syringe was titrated into a sample cell
Vcontaining 22 M vIL-10M1, 11 M vIL-10M1A87I, or 10 M hIL-
b10M1. The first injection of 2 l was followed by 15 successive
minjections, each of 16.5 l, with a 4 min interval between injections
for vIL-10M1 and vIL-10M1A87I experiments. For hIL-10M1 experi- d
Vment, 30 successive injections, each of 8.25 l, were carried out
after the first injection of 2 l. After dilution correction, the titration V
dcurves were analyzed according to Wiseman et al. (1989) using OR-
IGIN version 5.0 (MicroCal). A 1:1 binding model was used to obtain ahe equilibrium association constant and enthalpy change. Com-
lexes formed during the ITC experiments were analyzed by size
xclusion chromatography confirming the 1:1 stoichiometry of the
omplexes.
PR Equilibrium Binding Assay
BIAcore 2000 instrument was employed to determine the affinity
f sIL-10R2 for the human and viral IL-10/sIL-10R1 complexes. Be-
ween 210 and 230 RU of hIL-10, vIL-10, cmvIL-10, and the control
igand, IFN-τ4 (Alexenko et al., 2000), were immobilized on research
rade CM5 sensor chips (Biacore) that had been activated with a
:1 mixture of 0.1 M N-hyroxysuccinimide and 0.1 M 3-(N,N-
imethylamino)-propyl-N-ethylcarbondiimide at the flow rate of 5
l/min. The activated surfaces were blocked by injecting 1 M etha-
olamine (5 l/min) for 7 min. Equilibrium binding experiments were
erformed by injecting sIL-10R2 at eight different concentrations
etween 0 and 700 M in the presence of 2 M sIL-10R1 at 25°C
n random order at the flow rate of 2 l/min for 6 min. Equilibrium
esponses were obtained by averaging the responses obtained in
he final 10 s of each injection. The contribution of sIL-10R2 to the
inding response was calculated by subtracting a baseline re-
ponse corresponding to solutions containing 2 M sIL-10R1 and
M sIL-10R2. The data were plotted against receptor concentra-
ion and fit to a 1:1 binding model.
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